Security key
Y1R80M106
CytoMed Therapeutics Ltd - Ordinary Shares (GDTC)
CUSIP: Y1R80M106
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Ordinary Shares
- Total 13F shares
- 7,032
- Total 13F value
- $7,243
- Share change
- +7,032
- SEC-reported price per share
- $1.03
- Number of holders
- 1
- Value change
- +$7,243
- Number of buys
- 1
- Shares outstanding
- 11,933,111
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
GDTC full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
CytoMed Therapeutics Ltd SEC filings
CytoMed Therapeutics Ltd company facts
Broader feeds
Reporting periods
Holder history for CUSIP Y1R80M106
Recent filing periods:
Ownership snapshot
Top reported holders of GDTC - CytoMed Therapeutics Ltd - Ordinary Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
mDR Ltd
Disclosed value leader
mDR Ltd
Comparable rows
9/13
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 11%
4 rows are not safely comparable across share classes.
13D/G row: mDR Ltd
Showing 1-6 of 13 holder rows.
Quick read
mDR Ltd leads the comparable SEC ownership view at 11%.
9 of 13 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens mDR Ltd's linked filing trail.
Comparable ownership
Top 5
mDR Ltd
11%
28 Consultants Ltd
7.6%
Yoong Ying Tan
0.22%
Yvonne Goh
0.22%
Keng Kiat Toh
0.03%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 13 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| mDR Ltd |
13D/G
|
11%
|
$3,112,881
1,307,933 shares
|
$0 | 16 Dec 2024 |
| 28 Consultants Ltd |
13D/G
|
7.6%
|
$2,095,145
880,313 shares
|
$0 | 17 Feb 2025 |
| Yoong Ying Tan |
3/4/5
Chief Corporate Officer
|
0.22%
|
$24,234
25,781 shares
|
— | 18 Mar 2026 |
| Yvonne Goh |
3/4/5
Chief Financial Officer
|
0.22%
|
$24,234
25,781 shares
|
— | 18 Mar 2026 |
| Keng Kiat Toh |
3/4/5
Director
|
0.03%
|
$4,040
4,000 shares
|
— | 18 Mar 2026 |
| Chak Hua Yew |
3/4/5
Director
|
0.02%
|
$2,320
2,469 shares
|
— | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
7,032
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
3
Q2 2026 holders
1
Holder diff
-2
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend